Drug Profile
Research programme: anti-Flightless I antibody - AbRegen
Alternative Names: Anti-Flightless I antibody - AbRegenLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator University of South Australia
- Developer AbRegen
- Class Antibodies; Skin disorder therapies
- Mechanism of Action FLII protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epidermolysis bullosa
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Epidermolysis-bullosa in Australia (Topical)
- 08 Jul 2019 Preclinical development in Epidermolysis bullosa is ongoing in Australia (Topical) (AbRegen pipeline, July 2019)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Epidermolysis-bullosa in Australia (Topical)